title: Three new agents added to the arsenal to fight MRSA.
authors.affiliation: South Dakota State University College of Pharmacy, USA.
authors.forename: Joe
authors.initials: J
authors.lastname: Strain
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D006020:Glycopeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D010755:Organophosphates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010080:Oxazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D017334:Teicoplanin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010755:Organophosphates; D010080:Oxazoles; D017334:Teicoplanin; C469289:dalbavancin; C515040:tedizolid phosphate; C100708:oritavancin; D014640:Vancomycin